Under construction – not a live service
Sign in
Taking people in Hong KongNo phase

AI-assisted tests to assess risk of prostate cancer in men

Tests urine, blood, and AI-assisted scans in men at risk of prostate cancer.

Plain-language title generated from the registry record
Registry title: Artificial Intelligence (AI)-Assisted Risk-based Prostate Cancer Detection

Key facts

Where
Hong Kong, Hong KongSee the site

Where in Hong Kong

  • Prince of Wales Hospital, Chinese University of Hong KongHong Kong, Hong KongTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Chinese University of Hong Kong
Trial code
NCT05443412
Record updated
3 November 2026
Original description
This is a prospective clinical study recruiting 510 men at risk of PCa to undergo urine, blood, AI-assisted ultrasound and AI-assisted MRI investigations to stratify risk of clinically significant PCa (csPCa). (sample size calculation in section 5)Read full original descriptionShow less

Artificial Intelligence (AI)-Assisted Risk-based Prostate Cancer Detection: A Synergy of Novel Biomarkers, Advanced Imaging, and Robotic-assisted Diagnosis

This is a prospective clinical study recruiting 510 men at risk of PCa to undergo urine, blood, AI-assisted ultrasound and AI-assisted MRI investigations to stratify risk of clinically significant PCa (csPCa). (sample size calculation in section 5)

Inclusion: Men ≥18 years of age; Clinical suspicion of prostate cancer; Serum Prostate-specific antigen (PSA) 4-20 ng/mL; Digital rectal examination ≤ cT2 (organ confined cancer); Able to provide written informed consent.

Exclusion: Prior prostate biopsy; Past or current history of prostate cancer; Contraindicated to transperineal prostate biopsy: active urinary tract infection, fail TRUS probe insertion or lithotomy position, uncorrectable coagulopathy, antiplatelet or anticoagulant which cannot be stopped; Contraindicated to undergo plain MRI scan (e.g. pacemaker in-situ, claustrophobia).

ClinicalTrials.gov NCT05443412